Tengion Inc. to Participate in Panel Discussion at International Society for Stem Cell Research 11th Annual Meeting
WINSTON-SALEM, N.C., June 12, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Dr. Tim Bertram, the Company's President of Research and Development and Chief Scientific Officer, will participate in a panel at the International Society for Stem Cell Research (ISSCR) 11th Annual Meeting being held June 12th-15th, 2013 in Boston, Massachusetts.
Dr. Bertram will take part in a panel discussion titled "Disease-focused Research: From Bench to Bedside" on Thursday, June 13, 2013 at 11:30am to 12:30pm ET and will cover Tengion's groundbreaking research on the regeneration of the kidney and hollow organs.
Tengion's platform applies cell-based technologies for tissue and organ regeneration using a patient's own cells. The company's novel and proprietary technology identifies these cells and uses them to create a neo-organ, with the potential to develop new organs and tissues on a commercial scale. Tengion has two clinical-stage products including the Neo-Urinary Conduit designed to establish a new standard of care for bladder cancer patients undergoing cystectomy and the Neo-Kidney Augment intended to delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease.
ISSCR is the largest international interdisciplinary forum dedicated to stem cell science. Shinya Yamanaka, M.D., Ph.D., the current president, was awarded the Nobel Prize for Physiology or Medicine in 2012 for the discovery that adult somatic cells can be reprogrammed to become pluripotent cells capable of developing into all tissues of the body.
About Tengion
Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company's most advanced product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company initiated a Phase 1 clinical trial in Sweden in May 2013 for the Neo-Kidney Augment, which is designed to prevent or delay dialysis kidney transplantation by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.
SOURCE Tengion, Inc.
Help employers find you! Check out all the jobs and post your resume.